Abits
ABTS
Digihost Technology
DGHI
CATHEDRA BITCOIN INC
CBTTF
SATO TECHNOLOGIES CORP
CCPUF
Intchains Group
ICG
US Stock MarketDetailed Quotes
PLX Protalix Biotherapeutics
- 1.710
- -0.030-1.72%
Close Dec 18 16:00 ET
- 1.710
- 0.0000.00%
Pre 08:00 ET
125.91MMarket Cap-11.40P/E (TTM)
1.770High1.600Low345.00KVolume1.600Open1.740Pre Close585.97KTurnover0.63%Turnover Ratio19.00P/E (Static)73.63MShares1.90052wk High3.88P/B93.62MFloat Cap0.82152wk Low--Dividend TTM54.75MShs Float1037.500Historical High--Div YieldTTM9.77%Amplitude0.700Historical Low1.698Avg Price1Lot Size
Trending US Stocks
U.S. Crypto Concept Stocks U.S. Crypto Concept Stocks
Companies involved in the creation, trade, and services of digital forms of money.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S. Crypto Concept Stocks, ranked from highest to lowest based on real-time market data. Companies involved in the creation, trade, and services of digital forms of money.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S. Crypto Concept Stocks, ranked from highest to lowest based on real-time market data.
Protalix Biotherapeutics Stock Forum
Protalix BioTherapeutics to Present Phase I PRX-115 Data in Late-Breaking Poster at ACR Convergence 2024
Protalix BioTherapeutics (NYSE American:PLX) announced it will present data from its phase I clinical trial of PRX-115, a recombinant PEGylated uricase product candidate for uncontrolled gout treatment, at the ACR Convergence 2024. The presentation, titled 'Prolonged Plasma Urate-Lowering After a Single Intravenous Administration of PRX-115,' will be del...
Protalix BioTherapeutics to Host In-Person Investor Day to Discuss Current Treatment Landscapes and Clinical Results for Fabry Disease and Uncontrolled Gout
Protalix BioTherapeutics (NYSE American: PLX), a biopharmaceutical firm, will host an in-person investor day on June 26, 2024, at the Lotte Palace New York Hotel. The event will begin at 8:30 a.m. EDT. Key opinion leaders, including Aleš Linhart of Charles University and Naomi Schlesinger of the Univers...
Protalix BioTherapeutics to Present at the 2024 BIO International Convention
Protalix BioTherapeutics (NYSE American: PLX), a biopharmaceutical company specializing in recombinant therapeutic proteins via its ProCellEx® plant cell-based system, announced its participation at the 2024 BIO International Convention in San Diego, California. The convention, hosted by the Biotechnology Innovation Organization (BIO), is the largest industry event, gathering glo...
positive EMA to be anounced. Possibly as early as tommorow
No comment yet